We read with interest the article published in The Journal of Rheumatology by Ogdie et al¹ in which apremilast monotherapy showed more benefit in a specific subset of the psoriatic arthritis (PsA) population (oligoarticular pattern), compared to methotrexate (MTX) and biologic disease-modifying antirheumatic drugs (bDMARDs). The authors collected baseline and follow-up data (6-month period) regarding the clinical response to either MTX, apremilast, or bDMARD, all in monotherapy.

中文翻译：

---

Apremilast 在寡关节银屑病关节炎中的应用。

我们饶有兴趣地阅读了Ogdie 等人在风湿病学杂志上发表的文章¹，其中与甲氨蝶呤 (MTX) 和生物疾病相比，阿普司特单药疗法对银屑病关节炎 (PsA) 人群（寡关节模式）的特定子集有更多益处-改良抗风湿药（bDMARDs）。作者收集了关于 MTX、apremilast 或 bDMARD 单药治疗的临床反应的基线和随访数据（6 个月）。